DongKoo Bio&Pharma Co. Ltd
DongKoo Bio&Pharma. Co., Ltd. researches, develops, manufactures, and sells medicines in South Korea. The company offers prescribed medicines, such as liver disease, skeletal muscle relaxant, endocrine system, brain nervous system, urogenital, antiobestic, digestive system, circulatory organ, allergenic, mental disease, oral dermatology, external preparation of dermatology, antiseptic, antiviral,… Read more
DongKoo Bio&Pharma Co. Ltd (006620) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.011x
Based on the latest financial reports, DongKoo Bio&Pharma Co. Ltd (006620) has a cash flow conversion efficiency ratio of 0.011x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩1.20 Billion) by net assets (₩110.66 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
DongKoo Bio&Pharma Co. Ltd - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how DongKoo Bio&Pharma Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
DongKoo Bio&Pharma Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DongKoo Bio&Pharma Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Elixir Energy Ltd
AU:EXR
|
-0.062x |
|
Intellistake Technologies Corp.
F:E41
|
-0.816x |
|
GATELEY (HLDGS) LS -10
F:5I2
|
N/A |
|
Srisawad Capital 1969 PCL
BK:SCAP
|
0.146x |
|
PLIANT THERA.INC.DL-0001
F:9PT
|
N/A |
|
Türk Traktör ve Ziraat Makineleri A.S
PINK:TTRKF
|
0.123x |
|
UHT Unitech Co., Ltd.
TWO:6618
|
-0.091x |
|
Bright Scholar Education Holdings Ltd Class A
NYSE:BEDU
|
-0.021x |
Annual Cash Flow Conversion Efficiency for DongKoo Bio&Pharma Co. Ltd (2015–2024)
The table below shows the annual cash flow conversion efficiency of DongKoo Bio&Pharma Co. Ltd from 2015 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩105.33 Billion | ₩17.34 Billion | 0.165x | +407.23% |
| 2023-12-31 | ₩110.44 Billion | ₩3.59 Billion | 0.032x | -80.29% |
| 2022-12-31 | ₩102.11 Billion | ₩16.82 Billion | 0.165x | -7.88% |
| 2021-12-31 | ₩100.12 Billion | ₩17.90 Billion | 0.179x | +126.00% |
| 2020-12-31 | ₩94.65 Billion | ₩7.49 Billion | 0.079x | -33.16% |
| 2019-12-31 | ₩85.65 Billion | ₩10.14 Billion | 0.118x | +1178.70% |
| 2018-12-31 | ₩72.10 Billion | ₩-791.20 Million | -0.011x | -104.36% |
| 2017-12-31 | ₩37.74 Billion | ₩9.51 Billion | 0.252x | -55.89% |
| 2016-12-31 | ₩22.05 Billion | ₩12.59 Billion | 0.571x | -79.00% |
| 2015-12-31 | ₩2.55 Billion | ₩6.93 Billion | 2.719x | -- |